Table 1 Baseline patient characteristics
ctDNA baseline | All patients (n = 85) | p value | ||
|---|---|---|---|---|
Undetectable (n = 35) | Detectable (n = 28) | |||
Median age | 59 (35–79) | 57.5 (27–82) | 57 (27–82) | |
Sex | ||||
Female | 20 (57.1) | 14 (50) | 48 (56.5) | 0.0572 |
Male | 15 (42.9) | 14 (50) | 37 (43.5) | |
ECOG | ||||
0 | 29 (82.9) | 12 (42.9) | 56 (65.9) | 0.004 |
1 | 4 (11.4) | 10 (35.7) | 21 (24.7) | |
2 | 2 (5.7) | 6 (21.4) | 8 (9.4) | |
Mutation | ||||
BRAF V600 E/K | 24 (68.6) | 22 (78.6) | 63 (74) | 0.374 |
NRAS Q61K/R/L/H G12D G13R | 11 (31.4) | 6 (21.4) | 22 (26) | |
Stage | ||||
III–IV1a, IV1b | 11 (31.4) | 3 (10.7) | 18 (21.2) | 0.049 |
IV-M1c | 24 (68.6) | 25 (89.3) | 67 (78.8) | |
Sites ≥ 3 | ||||
No | 24 (68.6) | 7 (25) | 38 (44.7) | < 0.001 |
Yes | 10 (28.6) | 21 (75) | 45 (52.9) | |
Unknown | 1 (2.9) | 0 (0.0) | 2 (2.4) | |
Brain | ||||
No | 21 (60) | 21 (75) | 54 (63.5) | 0.209 |
Yes | 14 (40) | 7 (25) | 31 (36.5) | |
LDH | ||||
≤ ULN | 29 (82) | 9 (32.1) | 46 (54.1) | < 0.001 |
> ULN | 6 (17.1) | 18 (64.3) | 37 (43.5) | |
Unknown | 0 (0.0) | 1 (3.6) | 2 (2.4) | |
CRP | ||||
≤ ULN | 22 (62.9) | 9 (32.1) | 38 (44.7) | 0.021 |
> ULN | 13 (37.1) | 18 (64.3) | 45 (52.9) | |
Unknown | 0 (0.0) | 1 (3.6) | 2 (2.4) | |
BOR | ||||
CR | 8 (22.9) | 3 (10.7) | 13 (15.3) | |
PR | 3 (8.6) | 2 (7.1) | 7 (8.2) | |
SD | 6 (17.1) | 3 (10.7) | 15 (17.6) | |
PD | 16 (46) | 20 (71.4) | 48 (56.5) | |
Unknown | 2 (5.7) | 0 (0.0) | 2 (2.4) | |
BRAF_MEK treatment | ||||
Yes | 20 (57.1) | 18 (64.3) | 51 (60) | 0.693 |
No | 15 (42.9) | 10 (35.7) | 34 (40) | |